Biologic safety in psoriasis: Review of long-term safety data

Journal of Clinical and Aesthetic Dermatology

Volumn 8, Issue 2, 2015, Pages 30-42

  Mansouri, Yasaman ^a   Goldenberg, Gary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CREATINE KINASE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TRIACYLGLYCEROL; USTEKINUMAB;

ABSCESS; ALLERGY; ARTHRALGIA; CARDIOVASCULAR DISEASE; CELLULITIS; DEMYELINATION; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL INFECTION; HEADACHE; HEART DISEASE; HUMAN; INFECTION; INFLUENZA; INFUSION RELATED REACTION; JAW ABSCESS; LOADING DRUG DOSE; LUNG TUBERCULOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MILIARY TUBERCULOSIS; NON MELANOMA SKIN CANCER; PHARYNGITIS; PNEUMONIA; PSORIASIS VULGARIS; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; SALMONELLOSIS; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TONSILLITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84922876311     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a populationbased study. Arch Dermatol. 2005;141(12):1537-1541.
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218- 224.
3. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147-151.
4. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031-1042.
5. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835.
6. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1-70.
7. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-1050.
8. Doherty SD, van voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217.
9. Tsai TF, Ho v, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5): 1145-1152.
10. Wu JJ, Poon Ky, Channual JC, Shen Ay. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244-1250.
11. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864-871.
12. Hugh J, van voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168-177.
13. Puig L, Camacho Martínez FM, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology. 2012;225(3): 220-230.
14. Kimball AB, Pariser D, yamauchi PS, et al. OBSERvE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013;68(5):756-764.
15. vender R, Lynde C, Gilbert M, et al. One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-tosevere plaque psoriasis in a Canadian population. J Cutan Med Surg. 2013;17(2):129-138.
16. Papp KA, Poulin y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33-e45.
17. Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an openlabel study. J Drugs Dermatol. 2010;9(8):928-937.
18. Tyring S, Gordon KB, Poulin y, et al. Long-term safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719-726.
19. van Lümig PP, van de Kerkhof PC, Boezeman JB, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol. 2013;27(5):593- 600.
20. Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.J Am Acad Dermatol. 2010;63(3):448-456.
21. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115.
22. Gordon K, Papp K, Poulin y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REvEAL. J Am Acad Dermatol. 2012;66(2):241-251.
23. Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014;171(3):631-641.
24. Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325-1334.
25. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1-e15.
26. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
27. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-1684.
28. Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Group JUS. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242- 252.
29. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844-854.
30. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262-2269.
31. Kimball AB, Wu y. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol. 2009;48(11):1147-1156.
32. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735-1741.
33. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862-872.
34. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38(6):573-588.
35. Smith CH, Anstey Av, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019.
36. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderateto-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513-526.
37. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2): 274-285.
38. Han G. In the pipeline for psoriasis: upcoming psoriasis treatments. Cutis. 2014;93(3):E12-E16.